Advertisement

Topics

Shire's ONIVYDE approved in Europe for pancreatic cancer

04:02 EDT 19 Oct 2016 | Pharmaceutical Business Review

The European Commission (EC) has granted marketing authorization for Shire's ONIVYDE (pegylated liposomal irinotecan hydrochloride trihydrate), also known as nal-IRI or MM-398, to treat metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine-based therapy.

Original Article: Shire's ONIVYDE approved in Europe for pancreatic cancer

NEXT ARTICLE

More From BioPortfolio on "Shire's ONIVYDE approved in Europe for pancreatic cancer"

Quick Search
Advertisement
 

Relevant Topic

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...